Synbio International Inc. has announced approval for Deposit/Withdrawal at Custodian and Direct Registration System processing through its transfer agent, Pacific Stock Transfer Company. This development represents a significant modernization of the company's trading infrastructure aimed at improving accessibility for both current shareholders and potential investors.
The DWAC eligibility enables electronic transfer of shares between broker-dealers and the company's transfer agent, eliminating the need for physical share certificates. This reduces settlement times and lowers transaction friction, creating more efficient trading in the open market. In parallel, DRS allows shareholders to hold their shares directly on the company's books in electronic form without requiring physical certificates or intermediary custody. This provides investors with greater control, enhanced ownership security, and simplified transferability.
Claudio Solitario, CEO of Synbio International, stated that achieving DWAC and DRS eligibility represents a foundational step in strengthening the company's capital markets platform. As Synbio continues to advance strategic initiatives including planned financing activities and partnership developments, having stock that is easily accessible and efficiently tradable for the investment community becomes critical. This positions the company to move quickly as it executes on multiple near-term initiatives currently in progress.
This development comes as Synbio continues transitioning toward a more investor-ready, execution-focused public company platform, with multiple near-term capital markets and operational catalysts expected. The company operates as a medical research and technology firm focused on clinically validated AI-driven medical diagnostics. Through strategic partnerships and research collaborations, Synbio aims to bridge the gap between wellness and medicine, developing science-based solutions that improve quality of life and empower healthcare providers.
The implications of this announcement extend beyond operational improvements to potentially broader market implications. By reducing settlement times and transaction friction, Synbio International may attract a wider range of investors who prioritize liquidity and efficient trading mechanisms. The enhanced security and control offered through DRS could appeal to long-term investors seeking direct ownership without intermediary risks. These infrastructure improvements position the company more competitively within the biotechnology and medical technology sectors where investor accessibility can influence capital formation and growth opportunities.
For current shareholders, the changes mean simplified portfolio management and potentially faster access to capital when trading shares. For prospective investors, the streamlined processes reduce barriers to entry, making Synbio International's stock more accessible through standard brokerage platforms. The company's website at https://www.synbiointl.com provides additional information about its operations and strategic direction.
As public companies increasingly modernize their trading infrastructure, Synbio International's move aligns with broader industry trends toward digital securities management. The combination of DWAC and DRS eligibility represents a comprehensive approach to shareholder services that balances efficiency with security, potentially serving as a model for other OTC-traded companies seeking to enhance their market presence and investor relations capabilities.
